NASDAQ (USD): Sangamo Therapeutics, Inc. (SGMO)
Last Price
2.17
Today's Change
-0.27 (11.06%)
Day's Change
2.09 - 2.54
Trading Volume
6,042,368
You are setting up a price and signal alert with 15 minutes delay. Click here to enjoy real-time price and signal alerts.
T4Q
31-Mar-2021
2020
2019
2018
2017
Stock Price
238
1000
110
900
600
MQ Chat
Send individual or group chats with anyone on i3investor
MQ Trader
Earn MQ Points while trading with MQ Trader
MQ Affiliate
Earn side income from Affiliate Program
MQdemy
Online learning and teaching marketplace
1
CEO Morning Brief
Trump in Phone Call Advised Putin Not to Escalate in Ukraine — Washington Post
2
US Ordered TSMC to Halt Shipments of Chips for AI to China — Reuters
3
Dogecoin Outperforms Bitcoin as Trump Spurs Crypto Speculation
4
Hedge Funds Shorting Tesla Just Lost More Than US$5 Bil
5
Trump Seeks Fast Appointments; Elon Musk Makes Endorsement for Senate Leadership
#
Stock
Score
MSTR
MicroStrategy Incorporated
AGN
833
BABA
Alibaba Group Holding Limited
666
KXIN
Kaixin Auto Holdings
BITF
Bitfarms Ltd.
6
AAPL
Apple Inc.
500
7
PLTR
Palantir Technologies Inc.
466
8
CHMT
333
9
UEIC
Universal Electronics Inc.
10
NOC
Northrop Grumman Corporation
Last
Change
Volume
ELAB
0.027
+0.002
1,673,354,129
XTIA
0.062
+0.005
335,307,275
MTEM
0.639
+0.317
296,872,726
SVMH
0.029
232,781,823
QUBT
4.18
+1.52
206,516,603
MVST
0.735
-0.06
160,960,413
UAVS
3.34
+1.73
160,280,830
NVDA
146.89
+0.62
140,130,329
LMDX
0.016
-0.018
120,553,903
BRK-A
702,931.04
+681.06
1,237
NVR
9,201.00
+95.33
9,700
MKL
1,709.27
+53.91
38,020
DDS
435.70
+47.19
147,925
BH-A
1,050.00
+33.00
972
ASML
698.63
+25.22
3,123,643
BLK
1,048.369
+17.39
511,680
SPOT
481.38
+14.01
3,798,202
CYBR
305.40
+13.79
598,034
FSLR
195.39
+13.26
3,314,597
MELI
1,774.05
-343.25
2,940,447
1,309.00
-138.99
2,237,917
1,395.13
-102.30
318,280
TDG
1,267.09
-95.91
375,299
NOW
643.29
-87.83
5,025,012
762.00
-84.71
85,558,284
MEDP
357.30
-79.88
1,004,401
MDB
236.06
-73.94
10,812,930
MCK
547.51
-70.00
4,067,959
1,877.49
-53.46
352,654
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....